(19)
(11) EP 1 244 460 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.05.2010 Bulletin 2010/20

(45) Mention of the grant of the patent:
31.03.2010 Bulletin 2010/13

(21) Application number: 00975204.9

(22) Date of filing: 23.10.2000
(51) International Patent Classification (IPC): 
A61K 31/44(2006.01)
A61K 31/24(2006.01)
A61P 35/00(2006.01)
A61P 9/10(2006.01)
 A61K 31/495(2006.01)
A61K 31/70(2006.01)
A61P 13/08(2006.01)
A61P 9/12(2006.01)
(86) International application number:
PCT/US2000/026271
(87) International publication number:
WO 2001/028568 (26.04.2001 Gazette 2001/17)

(54)

USE OF DIPYRIDINIUM COMPOUNDS FOR TREATING A DISEASE CHARACTERIZED BY PROLIFERATING CELLS CONTAINING NITRIC OXIDE SYNTHASE

VERWENDUNG VON DIPYRIDINIUM VERBINDUNGEN ZUR BEHANDLUNG VON KRANKHEITEN CHARAKTERISIERT DURCH PROLIFERIERENDE ZELLEN ENTHALTEND STICKSTOFFMONOXID-SYNTHASE

UTILISATION DE COMPOSÉS DU DIPYRIDINIUM POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR DES CELLULES PROLIFERANTES CONTÉNANTS DE L'OXYDE NITRIQUE SYNTHASE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 21.10.1999 US 421942

(43) Date of publication of application:
02.10.2002 Bulletin 2002/40

(73) Proprietors:
  • Duke University
    Durham, NC 27708-0083 (US)
  • CORNELL RESEARCH FOUNDATION, INC.
    Ithaca, NY 14850 (US)
  • National Jewish Medical and Research Center
    Denver, CO 80206 (US)

(72) Inventors:
  • STAMLER, Jonathan, S.
    Chapel Hill, NC 27514 (US)
  • DAY, Brian, J.
    Englewood, CO 80111 (US)
  • GRIFFITH, Owen, W.
    Milwaukee, WI 53210 (US)
  • GROSS, Steven, S.
    New York, NY 10038 (US)

(74) Representative: Burford, Anthony Frederick 
Beck Greener Fulwood House 12 Fulwood Place
London WC1V 6HR
London WC1V 6HR (GB)


(56) References cited: : 
US-A- 5 618 838
 US-A- 6 057 367
   
  • JAWORSKA A ET AL: "The effect of paraquat on the radiosensitivity of melanoma cells: the role of superoxide dismutase & catalase." FREE RADICAL RESEARCH COMMUNICATIONS. SWITZERLAND 1993, vol. 18, no. 3, 1993, pages 139-145, XP009029861 ISSN: 8755-0199
  • CARMINES E L ET AL: "INVESTIGATIONS INTO THE MECHANISM OF PARAQUAT TOXICITY UTILIZING A CELL CULTURE SYSTEM" TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 58, no. 3, 1981, pages 353-362, XP009029885 ISSN: 0041-008X
  • MORANDINI R ET AL: "SODs are involved in the regulation of ICAM-1 expression in human melanoma and endothelial cells" CELLULAR AND MOLECULAR BIOLOGY (NOISY-LE-GRAND), vol. 45, no. 7, November 1999 (1999-11), pages 1053-1063, XP009029862
  • DAY BRIAN J ET AL: "A mechanism of paraquat toxicity involving nitric oxide synthase" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 22, 26 October 1999 (1999-10-26), pages 12760-12765, XP002277944 Oct. 26, 1999 ISSN: 0027-8424
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).